Most Common Side Effects of Lurbinectedin
Lurbinectedin (Zepzelca), approved for small cell lung cancer, most often causes hematologic toxicities like neutropenia (57%), anemia (53%), and thrombocytopenia (45%). Fatigue (42%) and nausea (37%) also occur frequently.[1][2]
How These Compare to Clinical Trial Data
In the PM14 trial supporting FDA approval, grade 3-4 adverse events included neutropenia (62%), anemia (22%), and thrombocytopenia (19%). Non-hematologic effects like increased creatinine (42%) and decreased appetite (35%) were common but mostly mild to moderate.[1][3]
Side Effects Patients Report Most
Real-world use shows similar patterns: myelosuppression leading to infections, fatigue, and gastrointestinal issues like vomiting (28%) and diarrhea (20%). Hyponatremia (28%) and transaminitis (26%) are notable lab abnormalities.[2][4]
Serious Risks and Management
Severe effects include febrile neutropenia (7%), pneumonia (6%), and respiratory failure. Premedication with antiemetics and growth factors for neutropenia is standard. Dose reductions occurred in 30% of patients due to toxicity.[1][3]
Differences from Chemotherapy Alternatives
Compared to topotecan, lurbinectedin has higher rates of cytopenias but lower nausea and alopecia. It's often better tolerated in later lines.[3]
[1]: FDA Label for Zepzelca
[2]: Drugs.com - Lurbinectedin Side Effects
[3]: NEJM - Lurbinectedin in SCLC (PM14 Trial)
[4]: Medscape - Zepzelca Dosing & Side Effects